EUDRAGIT® Functional Polymers

Silica gel (silicon dioxide, CAS# 112926-00-8) for chromatography, batch extractions, decolorizations and more. Optimized particle size, surface area, pH, and purity make Chromatocel S series a particularly useful material for the separation of small molecules, peptides, lipids, alkaloids, botanical extrac...

For more than 20 years, Evonik has been the world’s largest process developer and manufacturer of HPAPIs, with a total capacity of 170m³ and OEL down to 5 ng/m³. In addition to the development and implementation of highly potent API manufacturing processes for most classical organic reaction types, we exce...

For more than three decades, Evonik has served as a reliable fermentation partner to pharmaceutical companies, as well as other innovators who are seeking to industrialize disruptive biofabrication technologies within promising markets such as advanced foods or nature-identical materials. We have...

PhytoSquene® is the world’s first GMP-quality, plant-derived squalene. It offers a sustainable and high-quality alternative to traditional shark-derived squalene, meeting the need for sustainably sourced pharmaceutical-grade squalene. The key drivers behind its development are sustainability, safety, regul...

EUDRACAPTM functional ready-to-fill capsules can optimize your release profile, protect your active ingredients, and help accelerate your speed to market. EUDRACAP™ is ideal for use with active ingredients which are sensitive to heat, moisture or gastric acid to optimize absorption and avoid premature ...

A new oral drug delivery technology providing enteric protection followed by rapid, homogeneous release for effective pH targeting of the upper small intestine where there is a narrow absorption window.

Find our presentation on the Evonik Oncare platform: https://oncare.evonik.com/media/?fil...

Noblyst® P products are precious metal powder catalysts on various support materials mostly used in batch and slurry processes. This brand also comprises a range designed for flow chemistry processes. Evonik provides a full service package, including precious metals management. With production sites in all...

Evonik is one of the world’s leading CDMOs for parenteral drug delivery. For complex parenteral drug products designed for systemic, targeted or localized delivery, we are uniquely positioned to serve as a global development partner and solutions provider. Our parenteral drug delivery portfolio includes th...

Plant-derived cholesterol for mRNA delivery, gene therapy and cell culture: Our plant-derived PhytoChol® provides you with a secure and stable supply of synthetic cholesterol. Evonik supplies PhytoChol® in two grades that are tailored to the specific needs of injectable drug delivery and biopharm...

Evonik has over three decades of experience formulating liposomes and lipid nanoparticles (LNPs) using variety of different lipids. Evonik also manufactures lipids, including those used in mRNA COVID-19 vaccines. We harbor a deep understanding of liposomes and LNPs, including formulation, scale up, and ...

Lipid nanoparticles (LNPs) enable the delivery of a variety of molecules, including nucleic acids such as mRNA, to cells and are therefore an essential tool in gene therapy. To unleash the potential of vaccines, protein and gene therapies, drug developers need the support of a trusted and experienced pro...

cQrex IS THE EVONIK BRAND FOR CELL CULTURE SOLUTIONS WITH SCIENTIFICALLY PROVEN BENEFITS
• Highly purified amino acids: the reliable basis forreproducible cell culture media performance
• Chemically defined boosters: peptides and ketoacidsovercoming key challenges in mammalian cell culture
•...

In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, which was held at CPHI Frankfurt, across the categories from digital innovation to CEO of the year. 

Video introduction to Evonik Healthcare, a global development partner and enabling solutions provider.

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). This polymer-based platform complements Evonik’s existing portfolio of lipid-based drug delivery, including LNPs.

EUDRAGIT® polymers have been used as coatings to create more effective drugs for 70 years.

Evonik offers an innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water. This technology has the potential to significantly reduce the environmental footprint of drug manufacturing by minimizing the need for large volumes of solvent and helping to simplify processes.

Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of LNP formulations.

Evonik has officially opened a new facility for drying aqueous dispersions of EUDRAGIT® polymers at its site in Darmstadt.

PhytoSquene® is the world’s first GMP-quality, plant-derived squalene. It offers a sustainable and high-quality alternative to traditional shark-derived squalene, meeting the need for sustainably sourced pharmaceutical-grade squalene. The key drivers behind its development are sustainability, safety, regulatory compliance and social responsibility. Extracting squalene from shark livers for use in parenteral pharmaceutical applications such as vaccines depletes shark populations, which impacts marine biodiversity. PhytoSquene® supports the UN Sustainable Development Goals (SDGs) of protecting ecosystems and promoting circularity, while also mitigating risks associated with bioaccumulative toxins found in animal sources, and ensuring batch-to-batch consistency and superior quality in compliance with European Pharmacopoeia standards. Made from amaranth oil and manufactured in Germany using proprietary technology, PhytoSquene® not only advances patient safety and acceptance, but also demonstrates Evonik’s commitment to next-generation solutions with a positive sustainability profile. PhytoSquene® provides vaccine manufacturers and patients peace of mind while protecting marine ecosystems.

EUDRACAP functional ready-to-fill capsules can optimize your release profile, protect your active ingredients, and help accelerate your speed to market.

Developing a delayed release formulation of acid-sensitive actives that can be used in solid dosage forms such as tablets, pellets and capsules can be costly. Usually several stages are involved starting from R&D development to scale up and validation steps, all of which require significant investment of time and money. Sourcing a ready-to-fill functional capsule is an effective way of saving costs, reducing time to market, and boosting the performance of oral drug delivery products. EUDRACAP is our recently launched non-animal-derived platform of functional, ready-to-fill capsules for fast-track development of sensitive drugs.